AimTo examine current evidence on health‐related quality of life and its associated factors in women with metastatic breast cancer over the past 10 years.DesignAn integrative review.Data SourcesWe conducted a comprehensive search across five databases: CINAHL, EMBASE, MEDLINE, PsycINFO, and Web of Science, for studies published between January 2013 and June 2023.Review MethodsFollowing the integrative review guideline, we screened full‐text papers based on the inclusion and exclusion criteria. The quality of the studies was assessed using the Joanna Briggs Institute's appraisal checklist, and the data were extracted and synthesised.ResultsOf 7316 articles, 25 studies met the inclusion criteria. Most of the participants were non‐Hispanic white women from the United States or Europe. Various instruments were used to assess health‐related quality of life. The key factors included sociodemographic and clinical characteristics, physical symptoms and function, disease stability and progression, and psychological attributes. Although targeted agents and immunotherapy are common therapies today, data on their side effects and health‐related quality of life remain limited. Literature gaps included a lack of racially diverse samples, an absence of data on protective factors, and limited insights into symptom experience with novel therapies.ConclusionsPhysical and psychological symptoms were still the major influencing factors. Clinicians should prioritise symptom management in women. Future research is needed to increase racial diversity in the study and explore novel agents related to symptoms and protective factors that may improve health‐related quality of life.ImpactWomen with metastatic breast cancer experience compromised health‐related quality of life. Understanding which factors influence their quality of life, particularly those on novel therapies is critical for providing high‐quality, individualised care and developing targeted interventions to improve their well‐being.Reporting MethodPRISMA.No Patient or Public ContributionThis integrative review does not need patient or public contribution.

中文翻译：

---

转移性乳腺癌女性健康相关生活质量的综合评价


目的检查过去 10 年转移性乳腺癌女性健康相关生活质量及其相关因素的当前证据。设计综合评价。数据来源我们在五个数据库中进行了全面检索：CINAHL、EMBASE、MEDLINE、PsycINFO 和 Web of Science，以查找 2013 年 1 月至 2023 年 6 月期间发表的研究。使用 Joanna Briggs Institute 的评估清单评估研究的质量，并提取和综合数据。结果在 7316 篇文献中，25 篇文献符合纳入标准。大多数参与者是来自美国或欧洲的非西班牙裔白人女性。使用各种工具评估与健康相关的生活质量。关键因素包括社会人口学和临床特征、躯体症状和功能、疾病稳定性和进展以及心理属性。尽管靶向药物和免疫疗法是当今的常见疗法，但有关其副作用和与健康相关的生活质量的数据仍然有限。文献空白包括缺乏种族多样化的样本、缺乏有关保护因素的数据以及对新疗法症状体验的见解有限。结论躯体和心理症状仍是主要影响因素。临床医生应优先考虑女性的症状管理。需要未来的研究来增加研究中的种族多样性，并探索与症状和保护因素相关的新药物，这些药物可能会改善与健康相关的生活质量。影响患有转移性乳腺癌的女性患者的健康相关生活质量受到影响。 了解哪些因素会影响他们的生活质量，尤其是那些接受新疗法的因素，对于提供高质量的个体化护理和制定有针对性的干预措施以改善他们的健康状况至关重要。报告患者或公众 MethodPRISMA.No 本综合评价不需要患者或公众的贡献。